| Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer D Poel, TE Buffart, J Oosterling-Jansen, HMW Verheul, J Voortman Experimental & molecular medicine 50 (3), e454-e454, 2018 | 77 | 2018 |
| miRNAs: micro-managers of anticancer combination therapies JR van Beijnum, E Giovannetti, D Poel, P Nowak-Sliwinska, AW Griffioen Angiogenesis 20, 269-285, 2017 | 74 | 2017 |
| Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib KJ Gotink, M Rovithi, RR de Haas, RJ Honeywell, H Dekker, D Poel, ... Cellular oncology 38, 119-129, 2015 | 66 | 2015 |
| Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer M Neerincx, D Poel, DLS Sie, NCT van Grieken, RC Shankaraiah, ... PloS one 13 (8), e0201809, 2018 | 28 | 2018 |
| Proteomic analysis of miR-195 and miR-497 replacement reveals potential candidates that increase sensitivity to oxaliplatin in MSI/P53wt colorectal cancer cells D Poel, LNC Boyd, R Beekhof, T Schelfhorst, TV Pham, SR Piersma, ... Cells 8 (9), 1111, 2019 | 27 | 2019 |
| Dendritic cell phenotype and function in a 3D co-culture model of patient-derived metastatic colorectal cancer organoids B Subtil, KK Iyer, D Poel, L Bakkerus, MAJ Gorris, JC Escalona, K Dries, ... Frontiers in immunology 14, 1105244, 2023 | 24 | 2023 |
| Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth M Rovithi, RR de Haas, RJ Honeywell, D Poel, GJ Peters, AW Griffioen, ... Journal of Experimental & Clinical Cancer Research 35, 1-11, 2016 | 22 | 2016 |
| A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer D Poel, EC Gootjes, L Bakkerus, W Trypsteen, H Dekker, HJ van der Vliet, ... Cancer medicine 9 (20), 7558-7571, 2020 | 11 | 2020 |
| Development of a miRNA‐based classifier for detection of colorectal cancer molecular subtypes RS Adam, D Poel, L Ferreira Moreno, JMA Spronck, TR de Back, ... Molecular oncology 16 (14), 2693-2709, 2022 | 9 | 2022 |
| Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer KK Iyer, NP van Erp, DVF Tauriello, HMW Verheul, D Poel Cancer Treatment Reviews 110, 102466, 2022 | 8 | 2022 |
| The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy AA van Zweeden, RCM Opperman, RJ Honeywell, GJ Peters, ... Cancer treatment and research communications 27, 100371, 2021 | 8 | 2021 |
| High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors SL Gerritse, M Labots, R Ter Heine, H Dekker, D Poel, DVF Tauriello, ... Cancers 14 (24), 6061, 2022 | 6 | 2022 |
| Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer D Poel, F Rustenburg, D Sie, HF van Essen, PP Eijk, E Bloemena, ... Oral Oncology 109, 104851, 2020 | 5 | 2020 |
| cDC2 plasticity and acquisition of a DC3‐like phenotype mediated by IL‐6 and PGE2 in a patient‐derived colorectal cancer organoids model B Subtil, IAE van der Hoorn, J Cuenca‐Escalona, AMD Becker, ... European Journal of Immunology, 2350891, 2024 | 4 | 2024 |
| High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids KK Iyer, D Poel, A Miggelenbrink, W Kerkhof, J Janssen, L Bakkerus, ... BJC Reports 2 (1), 29, 2024 | 3 | 2024 |
| The neo-open reading frame peptides that comprise the tumor framome are a rich source of neoantigens for cancer immunotherapy MV Martin, S Aguilar-Rosas, K Franke, M Pieterse, J Langelaar, ... Cancer immunology research 12 (6), 759-778, 2024 | 1 | 2024 |
| High-dose short-exposure of osimertinib robustly inhibits growth of patient-derived metastatic colorectal cancer organoids KK Iyer, D Poel, A Miggelenbrink, W Kerkhof, E van den Hombergh, ... Cancer Research 83 (7_Supplement), 4028-4028, 2023 | | 2023 |
| Elacridar potentiates sunitinib efficacy in colorectal cancer models D Poel, KK Iyer, B van Gasteren, B Dagniaux, E van den Hombergh, ... Cancer Research 83 (7_Supplement), 418-418, 2023 | | 2023 |
| Exposure-response relation in metastatic colorectal cancer organoids after high-dose short-term tyrosine kinase inhibitor exposure K Iyer, A Miggelenbrink, D Poel, E van den Hombergh, L de Jong, ... European Journal of Cancer 174, S22, 2022 | | 2022 |
| Development of a miRNA-based classifier for molecular colorectal cancer subtypes RS Adam, D Poel, LF Moreno, J Spronck, TR de Back, F Markowetz, ... EUROPEAN JOURNAL OF HUMAN GENETICS 30 (SUPPL 1), 388-389, 2022 | | 2022 |
